Strides announcesQ4FY20 and FY20 Financial results
Key highlights include: Strides reports strong performance in FY20 despite Ranitidine withdrawal from the US market Adjusted FY20 revenues at ₹29,127 million with 33% YoY growth, Reported revenues grew by 26% FY20 Adjusted EBITDA at…









